Document is current
Any future updates will be listed below
-
Authors
Kimura, Kimitoshi https://orcid.org/0000-0002-8359-2886
Subramanian, Ayshwarya https://orcid.org/0000-0002-4134-7612
Yin, Zhuoran
Khalilnezhad, Ahad https://orcid.org/0000-0001-6492-0517
Wu, Yufan https://orcid.org/0000-0001-9277-2515
He, Danyang
Dixon, Karen O. https://orcid.org/0000-0001-7811-5439
Chitta, Udbhav Kasyap
Ding, Xiaokai https://orcid.org/0000-0002-5844-5008
Adhikari, Niraj
Guzchenko, Isabell https://orcid.org/0009-0004-3112-963X
Zhang, Xiaoming
Tang, Ruihan
Pertel, Thomas
Myers, Samuel A. https://orcid.org/0000-0001-7636-0887
Aastha, Aastha
Nomura, Masashi https://orcid.org/0000-0001-6095-7849
Eskandari-Sedighi, Ghazaleh https://orcid.org/0000-0003-0447-7722
Singh, Vasundhara https://orcid.org/0000-0001-8391-8527
Liu, Lei https://orcid.org/0000-0002-4604-4629
Lambden, Conner
Kleemann, Kilian L. https://orcid.org/0000-0002-2753-6804
Gupta, Neha
Barry, Jen-Li
Durao, Ana
Cheng, Yiran
Silveira, Sebastian
Zhang, Huiyuan
Suhail, Aamir https://orcid.org/0000-0001-8742-249X
Delorey, Toni https://orcid.org/0000-0001-6614-3803
Rozenblatt-Rosen, Orit
Freeman, Gordon J. https://orcid.org/0000-0002-7210-5616
Selkoe, Dennis J. https://orcid.org/0000-0001-8846-9767
Weiner, Howard L.
Blurton-Jones, Mathew https://orcid.org/0000-0002-7770-7157
Cruchaga, Carlos https://orcid.org/0000-0002-0276-2899
Regev, Aviv https://orcid.org/0000-0003-3293-3158
Suvà, Mario L. https://orcid.org/0000-0001-9898-5351
Butovsky, Oleg https://orcid.org/0000-0003-0186-8867
Kuchroo, Vijay K. https://orcid.org/0000-0001-7177-2110
- License Information
-
More Information
Article History
Received: 29 January 2023
Accepted: 28 February 2025
First Online: 9 April 2025
Competing interests
: G.J.F. has equity in Nextpoint, iTeos, IgM, Invaria, GV20, Bioentre and Geode. G.J.F. has served on advisory boards for iTeos, NextPoint, IgM, GV20, IOME, Bioentre, Santa Ana Bio, Simcere of America and Geode. G.J.F.’s interests were reviewed and managed by the Dana-Farber Cancer Institute in accordance with their conflict-of-interest policies. D.J.S. is a director of Prothena Biosciences and an ad hoc consultant to Roche and Eisai. M.B.-J. is a co-founder and consultant for Savanna Biotherapeutics (formally NovoGlia). A.R. is a cofounder and equity holder of Celsius Therapeutics, an equity holder in Immunitas and was a scientific advisory board member of ThermoFisher Scientific, Syros Pharmaceuticals, Neogene Therapeutics and Asimov until 31 July 2020. From 1 August 2020, A.R. is an employee of Genentech and has equity in Roche. M.L.S. is an equity holder, scientific cofounder and advisory board member of Immunity Therapeutics. O.B. is a cofounder of and has an ownership interest in Glial Therapeutics and Gliax. O.B. has a financial interest in Glial Therapeutics, a company developing a new therapy to target ITGB8–TGFβ signalling as a treatment for AD. O.B.’s interests were reviewed and are managed by Brigham and Women’s Hospital and Mass General Brigham in accordance with their conflict-of-interest policies and include collaboration with GSK and Regulus Therapeutics, receiving research funding from Sanofi and GSK, and honoraria for lectures and consultancy from UCB, Camp4 and Ono Pharma USA. V.K.K. has an ownership interest in Tizona Therapeutics, Trishula, Celsius Therapeutics, Bicara Therapeutics, Larkspur Therapeutics and Werewolf Therapeutics. V.K.K. has financial interests in Biocon Biologic, Compass, Elpiscience Biopharmaceutical, Equilium, PerkinElmer and Syngene. V.K.K. is a member of SABs for Cell Signaling Technology, Elpiscience Biopharmaceutical, Larkspur, Tizona Therapeutics, Tr1X and Werewolf. V.K.K.’s interests were reviewed and managed by Mass General Brigham in accordance with their conflict-of-interest policies.
